Unanswered Questions Remain Regarding SBRT in Gastrointestinal Cancers

September 24, 2019

Amol K. Narang, MD, discusses the unanswered questions that still need to be addressed to further expand the role of stereotactic body radiation therapy in gastrointestinal cancers.

Amol K. Narang, MD, assistant professor of radiation oncology and molecular radiation sciences at John Hopkins Medicine, discusses the unanswered questions that still need to be addressed to further expand the role of stereotactic body radiation therapy (SBRT) in gastrointestinal (GI) cancers. Pancreatic cancer, in particular, poses additional challenges compared with other GI cancers, Narang says.

Investigators question how SBRT fits in the treatment landscape with nonoperative therapies, such as transarterial chemoembolization (TACE). Narang says these 2 therapies may need to be compared, but there may also be rationale to combine both SBRT and TACE in some GI cancers.